Acurx Pharmaceuticals (ACXP) Q4 2024 earnings summary

Executive summary

• Preparing to advance ibezapolstat (IBZ) for C. difficile infection into international phase III clinical trials, with regulatory alignment from both FDA and EMA and positive phase IIb results showing high clinical cure and sustained cure rates, outperforming vancomycin.

• Recent scientific publications highlight IBZ's selective microbiome effects and anti-recurrence potential, differentiating it from other antibiotics.

• New patent granted in Japan for DNA polymerase IIIC inhibitors, supporting pipeline expansion and preclinical candidate ACX-375C.

• Raised $6.6 million in 2024 through ATM financing, plus $2.5 million and $1.1 million in direct offerings in January and March 2025.

Financial highlights

• Ended 2024 with $3.7 million in cash, down from $7.5 million at end of 2023.

• Research and development expenses for 2024 were $5.4 million, down from $6 million in 2023.

• General and administrative expenses for 2024 were $8.7 million, up from $8.5 million in 2023.

• Reported a net loss of $14.1 million ($0.87/share) for 2024, compared to $14.6 million ($1.15/share) in 2023.

• 17,030,686 shares outstanding as of December 31, 2024.

Outlook and guidance

• Phase III trial protocol is identical for FDA and EMA, with 150 sites planned (50% in Europe, 30% in the U.S.), and trial start anticipated in 2025, pending funding.

• Full phase II data publication expected within 30 days.

• Funding for phase III expected from partnerships or government grants.

• Top-line phase III data expected two years after first patient enrollment.

• Ongoing development of preclinical pipeline, including ACX-375C for MRSA, VRE, and anthrax.